Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Christopher G. Kanakry et al.|Blood|2015Cited by 299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adultsHeather J. Symons, Ephraim J. Fuchs, Marianna Zahurak et al.|Blood Advances|2020Cited by 73